Physician profile
Nicole Fore
NPI 1881170686
$541.84
in general payments reported to CMS, 2019-2025
11 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $250 · 2024: $14.13 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $146.11 | 2022-2025 | Ozempic |
| Glaxosmithkline, LLC. | $124.89 | 2022 | |
| Lilly USA, LLC | $61.78 | 2025 | Kisunla, Mounjaro, Zepbound |
| Pfizer INC. | $46.65 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $33.58 | 2025 | Austedo Xr |
| Amgen INC. | $28.43 | 2024-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $23.46 | 2025 | The Cologuard Plus Collection Kit |
| Solventum Corporation | $22.81 | 2025 | Activ.A.C. |
| Heartflow, INC. | $20.32 | 2025 | |
| Aimmune Therapeutics, INC. | $18.20 | 2025 | Zenpep |
| Sumitomo Pharma America, INC. | $15.61 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Fore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.